Equifax (EFX) Competitors $249.92 +4.30 (+1.75%) Closing price 03:59 PM EasternExtended Trading$250.00 +0.07 (+0.03%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EFX vs. CCRN, CRAI, APTV, FI, IQV, IT, OMC, RHI, TRU, and WMShould you be buying Equifax stock or one of its competitors? The main competitors of Equifax include Cross Country Healthcare (CCRN), Charles River Associates (CRAI), Aptiv (APTV), Fiserv (FI), IQVIA (IQV), Gartner (IT), Omnicom Group (OMC), Robert Half (RHI), TransUnion (TRU), and Waste Management (WM). Equifax vs. Its Competitors Cross Country Healthcare Charles River Associates Aptiv Fiserv IQVIA Gartner Omnicom Group Robert Half TransUnion Waste Management Equifax (NYSE:EFX) and Cross Country Healthcare (NASDAQ:CCRN) are both business services companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do insiders and institutionals have more ownership in EFX or CCRN? 96.2% of Equifax shares are held by institutional investors. Comparatively, 96.0% of Cross Country Healthcare shares are held by institutional investors. 1.4% of Equifax shares are held by company insiders. Comparatively, 4.9% of Cross Country Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer EFX or CCRN? In the previous week, Equifax had 25 more articles in the media than Cross Country Healthcare. MarketBeat recorded 27 mentions for Equifax and 2 mentions for Cross Country Healthcare. Equifax's average media sentiment score of 1.53 beat Cross Country Healthcare's score of -0.67 indicating that Equifax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equifax 21 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Cross Country Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has more risk & volatility, EFX or CCRN? Equifax has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Cross Country Healthcare has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Is EFX or CCRN more profitable? Equifax has a net margin of 10.95% compared to Cross Country Healthcare's net margin of -0.70%. Equifax's return on equity of 18.89% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Equifax10.95% 18.89% 7.84% Cross Country Healthcare -0.70%1.72%1.24% Do analysts prefer EFX or CCRN? Equifax currently has a consensus target price of $285.00, suggesting a potential upside of 14.04%. Cross Country Healthcare has a consensus target price of $17.93, suggesting a potential upside of 30.59%. Given Cross Country Healthcare's higher possible upside, analysts plainly believe Cross Country Healthcare is more favorable than Equifax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equifax 0 Sell rating(s) 7 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.70Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings & valuation, EFX or CCRN? Equifax has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Equifax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquifax$5.84B5.30$604.10M$5.1148.91Cross Country Healthcare$1.34B0.33-$14.56M-$0.26-52.81 SummaryEquifax beats Cross Country Healthcare on 15 of the 17 factors compared between the two stocks. Get Equifax News Delivered to You Automatically Sign up to receive the latest news and ratings for EFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFX vs. The Competition Export to ExcelMetricEquifaxConsulting IndustryBusiness SectorNYSE ExchangeMarket Cap$30.94B$6.74B$22.67B$20.88BDividend Yield0.81%1.75%2.82%3.59%P/E Ratio48.9123.3027.8128.34Price / Sales5.302.5439.9654.34Price / Cash19.3016.4126.1617.82Price / Book6.435.427.044.54Net Income$604.10M$272.15M$197.82M$992.74M7 Day Performance3.67%-0.08%9.46%0.30%1 Month Performance-5.08%-6.07%8.60%1.14%1 Year Performance-15.29%-8.83%37.47%11.01% Equifax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFXEquifax4.8503 of 5 stars$249.92+1.8%$285.00+14.0%-15.8%$30.94B$5.84B48.9114,700News CoveragePositive NewsCCRNCross Country Healthcare3.2611 of 5 stars$12.67-0.4%$17.93+41.5%-7.3%$415.10M$1.19B-48.738,205CRAICharles River Associates4.0807 of 5 stars$185.43-0.5%$228.00+23.0%+16.7%$1.22B$712.91M22.45940APTVAptiv4.5344 of 5 stars$66.80-0.2%$81.50+22.0%+9.8%$14.55B$19.79B15.29141,000News CoveragePositive NewsFIFiserv4.9702 of 5 stars$132.31-0.7%$207.08+56.5%-18.1%$71.92B$20.46B22.0938,000Trending NewsIQVIQVIA4.9099 of 5 stars$180.18+0.2%$228.62+26.9%-19.6%$30.63B$15.41B26.0788,000Trending NewsShort Interest ↓ITGartner4.9737 of 5 stars$226.00-1.3%$369.25+63.4%-50.5%$17.39B$6.42B13.9121,044High Trading VolumeOMCOmnicom Group4.3699 of 5 stars$72.98+0.0%$94.43+29.4%-21.1%$14.14B$15.69B10.4774,900News CoveragePositive NewsRHIRobert Half4.8546 of 5 stars$33.63-1.7%$45.83+36.3%-41.6%$3.42B$5.80B19.2114,700TRUTransUnion4.8581 of 5 stars$85.98-4.7%$112.46+30.8%-5.2%$16.75B$4.18B42.9913,400Positive NewsWMWaste Management4.9148 of 5 stars$237.13+0.9%$254.35+7.3%+9.2%$95.52B$23.95B35.1861,700Analyst Revision Related Companies and Tools Related Companies Cross Country Healthcare Alternatives Charles River Associates Alternatives Aptiv Alternatives Fiserv Alternatives IQVIA Alternatives Gartner Alternatives Omnicom Group Alternatives Robert Half Alternatives TransUnion Alternatives Waste Management Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EFX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equifax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equifax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access